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Original Research Paper
A real-world comparison of relapse rates,
healthcare costs and resource use among
patients with multiple sclerosis newly
initiating subcutaneous interferon beta-1a
versus oral disease-modifying drugs
James D Bowen , Chris M Kozma, Megan M Grosso and Amy L Phillips
Abstract
Background: Administrative-claims data enable comparative effectiveness assessment using large
numbers of patients treated in real-world settings.
Objective: To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly
initiating subcutaneous interferon beta-1a (sc IFNb-1a) v. oral disease-modifying drugs (DMDs: dimeth-
yl fumarate, fingolimod, teriflunomide).
Methods: Patients from an administrative claims database (1 Jan 2012–31 Dec 2015) were selected if
they: were 18–63 years old; had an MS diagnosis; had newly initiated sc IFNb-1a, dimethyl fumarate,
fingolimod, or teriflunomide (first claim¼ index); had no evidence of DMD 12-months pre-index; and
had 12-month eligibility pre- and post-index. Relapse was defined as an MS-related inpatient stay,
emergency room visit, or outpatient visit with a corticosteroid prescription 7 days. Outcomes were
evaluated using logistic regression and generalized linear models.
Results: A total of 4475 patients met inclusion criteria: 21.9% sc IFNb-1a, 51.0% dimethyl fumarate,
19.7% fingolimod, 7.4% teriflunomide. Teriflunomide patients had 1.357 (95% CI 1.000, 1.831;
p¼ 0.0477) greater odds of 1-year relapse than sc IFNb-1a patients. Estimated mean all-cause 1-year
costs were higher after fingolimod (US$72,376) v. sc IFNb-1a initiation (US$65,408; p< 0.0001). Non-
DMD costs were not significantly different.
Conclusion: Patients initiating sc IFNb-1a had better relapse outcomes v. teriflunomide, and lower
all-cause costs v. fingolimod.
Keywords: Multiple sclerosis, disease-modifying drugs, retrospective database, relapse, cost,
resource use
Date received: 24 August 2018; Revised received 30 October 2018; accepted: 11 November 2018
Introduction
The efficacy of self-injectable and oral disease-
modifying drugs (DMDs) in multiple sclerosis
(MS) has been demonstrated in clinical trials; how-
ever, limited real-world evidence (RWE) for the
comparative effectiveness of self-injectable and
oral DMDs currently exists. Seven published RWE
studies comparing subcutaneous interferon beta-1a
(sc IFNb-1a) v. oral DMDs did not evaluate sc
IFNb-1a individually, but rather combined it with
other IFNs and/or with glatiramer acetate.1–7 Six of
the seven studies compared relapse outcomes,1–6 two
compared disability progression,4,5 one compared
healthcare resource use and costs,6 and one
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compared adherence and persistence7 in patients
treated with interferons/glatiramer acetate v. patients
treated with oral DMDs.2–7 In general, study find-
ings showed that fingolimod and dimethyl fumarate
had favourable clinical outcomes compared with
IFNs and/or glatiramer acetate.1–7 Only one pub-
lished RWE study, a retrospective chart review,
directly compared sc IFNb-1a with an oral DMD,
dimethyl fumarate.8 Study findings showed that
patients treated with sc IFNb-1a had comparable
persistence and relapse outcomes, and better safety
outcomes, compared with patients treated with
dimethyl fumarate over 2 years.8
Administrative healthcare-claims databases provide
an opportunity to assess comparative effectiveness
of DMDs using large numbers of patients treated in
real-world settings.9,10 The objective of this study was
to utilize real-world data to evaluate relapses, health-
care costs and resource use of patients with MS newly
initiating sc IFNb-1a v. oral DMDs (teriflunomide,
fingolimod, and dimethyl fumarate).
Materials and methods
Data source
This retrospective database analysis used data from
the IQVIA
VR
Health Real-World Data Adjudicated
Claims – US database from between January 1,
2012 and December 31, 2015. This anonymous,
patient-centric database consists of fully adjudicated
medical and pharmacy health plan claims data (costs
and descriptive services) and enrollment information
for persons with commercial insurance coverage.
Data for more than 150 million unique enrollees
has been obtained from health plans and self-
insured employer groups throughout the USA since
2006. Claims represent provider payments for serv-
ices rendered to health plan individuals who are cov-
ered. The patient-level enrollment information is a
record of demographic variables including eligibility
status (year of birth, gender, US Census region, eli-
gibility by month). The database enrollee population
is generally representative of the < 65 years of age,
commercially insured population in the USA with
respect to both age and gender. More than 30 million
patients have three or more years of continuous
enrollment (medical and pharmacy coverage), and
the average length of enrollment is 39 months.
Each contributing plan’s data undergoes rigorous
data quality review by IQVIA. No institutional
review board approval is necessary as the database
is de-identified and compliant with the Health
Insurance Portability and Accountability Act
of 1996.
Patient population
Inclusion criteria: selected patients aged 18–63 years
with at least one medical claim with a diagnosis of
MS (International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) code:
340) and at least one prescription for sc IFNb-1a,
teriflunomide, fingolimod, or dimethyl fumarate
after MS diagnosis. The date of the first DMD pre-
scription claim (i.e. dispensing dates) was defined as
the index date. To examine patients new to therapy,
any patient with a DMD during the 12 months prior
to the index date was excluded. Continuous eligibil-
ity for 12 months before and after the index date was
also required. A 1-year follow-up period was used in
order to maximize capture of adequate numbers of
dimethyl fumarate patients, as dimethyl fumarate
was only approved by the US Food and Drug
Administration (FDA) for use in early 2013.
DMD treatment outcomes and covariates
Primary outcomes were relapses and non-DMD
healthcare costs. All-cause healthcare costs and
resource utilization were secondary outcomes.
Relapse was assessed 12 months following DMD
initiation and was defined as presence of 1 MS-
related (MS in the first diagnosis field) inpatient
stay, 1 MS-related emergency room (ER) visit,
or 1 MS-related outpatient visit with a corticoste-
roid claim 7 days of that visit. All-cause healthcare
costs and all-cause healthcare costs excluding DMD
costs were assessed 12 months following DMD ini-
tiation. Post-index resource utilization (i.e. visits,
laboratory tests and inpatient stays) was evaluated
to better understand differences in healthcare costs.
Covariates were qualitatively selected to reflect
potential differences in demographics, clinical
status and costs. This administrative database only
contained data for paid insurance claims. Given that
there are no clinical data, an attempt was made to
use the available data to develop a range of variables
that might be expected to affect utilization or costs;
these included variables that reflected patient
characteristics, comorbid conditions, MS-related
resource use in close proximity to the start of the
medication (as a proxy for near-term severity) and
12-month pre-index all-cause healthcare cost (as an
indicator of overall severity). Covariates included
age, sex, census region, 12-month pre-index comor-
bidities (depression-related, thyroid and inflammato-
ry/autoimmune, and Charlson Comorbidity Index
(CCI) score11,12), 90-day pre-index resource use
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(neurology visit or magnetic resonance imaging
(MRI)), 90-day pre-index relapse and 12-month
pre-index all-cause healthcare costs dichotomized
as above or below the median. The 90-day pre-
index period for the clinical variables was used as
a proxy for a patient’s MS disease status near the
time of therapy initiation. Pre-index all-cause health-
care costs in the year prior to DMD initiation were
used as a proxy for overall health severity. Costs
were dichotomized as above and below the median
due to the expected skewed distribution. As the
study period extended over multiple years, all
healthcare costs were discounted to December
2015 using the medical care services component of
the Consumer Price Index.13
Univariate analyses
Baseline demographic and clinical characteristics
were compared between index DMD cohorts (i.e.
sc IFNb-1a, teriflunomide, fingolimod, or dimethyl
fumarate) and included sex, age, census region, 12-
month pre-index comorbidities and indicators for
having a 90-day pre-index neurology visit, 90-day
pre-index MRI, 90-day pre-index relapse, pre-index
all-cause costs above the median for the sample and
12-month post-index relapse. Categorical and binary
variables were summarized using frequencies and
percentages. Continuous variables were summarized
using means (with confidence intervals (CIs)), stan-
dard deviations and medians. Pairwise Chi-square
tests were conducted using sc IFNb-1a as the refer-
ence group (i.e. all pairwise comparisons were with
sc IFNb-1a; no other comparisons were evaluated).
Continuous variables were assessed with t-tests
using sc IFNb-1a as the reference group. No correc-
tion was made for multiple testing among the uni-
variate tests.
Multivariable analysis
Logistic regression was used to evaluate the likeli-
hood of relapse (i.e. MS-related inpatient stay,
MS-related ER visit, or MS-related outpatient visit
with a corticosteroid prescription 7 days of that
visit) with sc IFNb-1a compared with teriflunomide,
fingolimod, or dimethyl fumarate as predictors of
interest. Covariates included demographics, clinical
status and cost variables measured at baseline as
listed above. Generalized linear models with a
gamma distribution and log link were used to
assess post-index healthcare costs using the same
model as the logistic regression model for relapse.
Models were evaluated for interactions with the
DMD treatment variable. Odds ratios (ORs) and
95% CIs for the odds of having a relapse are
reported. Generalized linear models, using the
same covariates, were also used for evaluation of
secondary resource utilization variables including
outpatient visits, neurology visits, liver function
tests (LFTs), complete blood count tests, MS and
all-cause inpatient stay and total inpatient days,
and MS and all-cause ER visits. All analyses were
performed using SAS for Windows version 9.4 (SAS
Institute Inc., Cary, NC, USA).
Results
Baseline and pre-index characteristics
Inclusion criteria were met by 4475 patients (978
(21.9%) sc IFNb-1a, 330 (7.4%) teriflunomide,
883 (19.7%) fingolimod, 2284 (51.0%) dimethyl
fumarate; Figure 1). Patients initiating sc IFNb-1a
were statistically significantly younger, and there
was a significantly greater proportion from the
Midwest and a significantly lower proportion from
the West compared with patients initiating oral
DMDs (Table 1). A significantly greater proportion
of patients initiating teriflunomide and dimethyl
fumarate were from the Northeast compared with
patients initiating sc IFNb-1a. A significantly
lower proportion of patients initiating dimethyl
fumarate were from the South compared with sc
IFNb-1a patients.
Patients initiating sc IFNb-1a had a statistically sig-
nificantly higher mean CCI score during the year
prior to the index date compared with patients initi-
ating fingolimod. A significantly smaller proportion
of patients initiating sc IFNb-1a had depression-
related comorbidities compared with patients initiat-
ing fingolimod and dimethyl fumarate. A signifi-
cantly smaller proportion of patients initiating sc
IFNb-1a had thyroid disease and inflammatory or
autoimmune disease compared with patients initiat-
ing teriflunomide. A significantly greater proportion
of patients initiating dimethyl fumarate had a 90-day
pre-index neurology visit compared with patients
initiating sc IFNb-1a. A significantly greater propor-
tion of patients initiating sc IFNb-1a had a 90-day
pre-index MRI compared with patients initiating
teriflunomide, fingolimod and dimethyl fumarate.
A greater proportion of patients initiating terifluno-
mide, fingolimod, and dimethyl fumarate had
all-cause pre-index year healthcare costs at or
above the median compared with patients initiating
sc IFNb-1a. A greater percentage of sc IFNb-1a
patients had a relapse in the 90-day pre-index
period compared with patients initiating terifluno-
mide, fingolimod, or dimethyl fumarate. Among
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the components of relapse in the 90-day pre-index
period, statistically significant differences were
observed for presence of an MS-related inpatient
stay or presence of an MS-related ER visit (Table 1).
DMD treatment outcomes: relapse
Unadjusted analysis. In the 1-year post-index
period, there were no statistically significant differ-
ences (unadjusted) in the percentages of patients
with a relapse or in the components of relapse
(Table 2).
Multivariable analysis. A multivariable analysis
was used to control for baseline differences among
the treatment groups. The logistic regression showed
an adequate fit based on the Hosmer–Lemeshow sta-
tistic (p¼ 0.2161; values> 0.05 are acceptable). The
Hosmer–Lemeshow goodness of fit test is frequently
used in risk prediction models to assess whether
observed event rates match expected event rates in
deciles of fitted risk values.14 The C-statistic, a mea-
sure of predictive accuracy, was 0.655 (values> 0.6
are acceptable), and the maximum R-squared for the
model was 7.5%. These statistics support the predic-
tive ability of the model.
After controlling for covariates in a logistic
regression, initiation of teriflunomide was associated
with a statistically significantly higher likelihood
of relapse (OR 1.357; p¼ 0.0477) relative to sc
IFNb-1a (Table 3). There was no statistically signif-
icant difference for fingolimod or dimethyl fumarate
relative to sc IFNb-1a. The only covariate associated
with statistically significantly lower odds of 1-year
post-index relapse was age. With each year of
increased age, the odds of 1-year post-index relapse
were 1.1% lower (OR 0.989; 95% CI 0.982, 0.996;
p¼ 0.0028). Statistically significant covariates asso-
ciated with increased odds of relapse included:
Midwest region (reference: West; OR 1.353, 95%
CI 1.032, 1.789; p¼ 0.0310), South region (refer-
ence: West; OR 1.324, 95% CI 1.010, 1.749;
p¼ 0.0450), depression-related comorbidities
(reference: depression not present; OR 1.226, 95%
CI 1.048, 1.433; p¼ 0.0107), neurology visit 90 days
pre-index (reference: no visit; OR 1.064, 95% CI
1.020, 1.116; p¼ 0.0091), relapse 90 days pre-
index (reference: no relapse; OR 2.146, 95% CI
1.823, 2.525; p< 0.0001), and pre-index all-cause
healthcare costs above the median (reference: costs
below median; OR 1.673, 95% CI 1.436, 1.950;
p< 0.0001). A significant interaction was observed
between census region in the East and the DMD
variable (p¼ 0.0080).
DMD treatment outcomes: healthcare costs and
resource use
After adjustment for baseline characteristics, least
squares mean estimated all-cause healthcare costs
1 year after fingolimod initiation (US$72,376)
Figure 1. Patient selection flowchart.
DMD: disease-modifying drug; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical
Modification; MS: multiple sclerosis; sc IFNb-1a: subcutaneous interferon beta-1a.
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Table 1. Baseline demographic and clinical characteristics of patients with MS newly initiating sc IFNb-1a,
teriflunomide, fingolimod, or dimethyl fumarate.
Characteristic
sc IFNb-1a
(n¼ 978)
Teriflunomide
(n¼ 330)
Fingolimod
(n¼ 883)
Dimethyl
fumarate
(n¼ 2284)
Age, years, mean (SD) 42.7 (10.4) 48.6 (8.5)b 43.9 (9.7)a 45.2 (10.3)b
Female, n (%) 716 (73.2) 255 (77.3) 668 (75.7) 1701 (74.5)
Census region, n (%)
Northeast 221 (22.6) 106 (32.1)b 227 (25.7) 629 (27.5)b
Midwest 342 (35.0) 85 (25.8)b 237 (26.8)b 682 (29.9)b
South 325 (33.2) 102 (30.9) 322 (36.5) 662 (29.0)a
West 66 (6.7) 34 (10.3)a 86 (9.7)a 274 (12.0)b
CCI score, mean (SD) 0.60 (1.22) 0.61 (1.06) 0.46 (0.96)b 0.59 (1.11)
Select comorbidities, n (%)
Depression related 240 (24.5) 99 (30.0) 268 (30.4)a 715 (31.3)b
Thyroid 130 (13.3) 71 (21.5)b 118 (13.4) 356 (15.6)
Inflammatory/autoimmune 33 (3.4) 21 (6.4)a 28 (3.2) 88 (3.9)
90-day pre-index neurology visit, n (%) 585 (59.8) 216 (65.5) 525 (59.5) 1499 (65.6)b
90-day pre-index MRI, n (%) 465 (47.5) 94 (28.5)b 227 (25.7)b 957 (41.9)b
All-cause pre-index year healthcare cost at
or above the median (US$12,158), n (%)
385 (39.4) 156 (47.3)a 482 (54.6)b 1215 (53.2)b
90-day pre-index relapse, n (%)
MS-related inpatient stay 63 (6.4) 4 (1.2)b 8 (0.9)b 55 (2.4)b
MS-related ER visit 23 (2.4) 6 (1.8) 10 (1.1)a 37 (1.6)
MS-related outpatient visit with
corticosteroid prescription7 days
223 (22.8) 68 (20.6) 183 (20.7) 484 (21.2)
Any relapse, n (%) 284 (29.0) 71 (21.5)a 195 (22.1)b 558 (24.4)a
Bold values denote statistically significant differences.
CCI: Charlson Comorbidity Index; ER: emergency room; MRI: magnetic resonance imaging; MS: multiple sclerosis;
sc IFNb-1a: subcutaneous interferon beta-1a; SD: standard deviation.
ap< 0.05 using pairwise Chi-square test or independent sample t-test v. sc IFNb-1a as the standard (no adjustment for
multiplicity).
bp< 0.005 using pairwise Chi-square test or independent sample t-test v. sc IFNb-1a as the standard (no adjustment for
multiplicity).
Table 2. Unadjusted relapse rates 1 year after DMD initiation among treatment groups (MS-related inpatient
stays, ER visits and outpatient relapses).
Characteristic
sc IFNb-1a
(n¼ 978)
Teriflunomide
(n¼ 330)
Fingolimod
(n¼ 883)
Dimethyl
fumarate
(n¼ 2284)
1-year post-index relapse, n (%)
MS-related inpatient stay 21 (2.1) 6 (1.8) 16 (1.8) 34 (1.5)
MS-related ER visit 24 (2.5) 13 (3.9) 16 (1.8) 37 (1.6)
MS-related outpatient visit with
corticosteroid prescription7 days
205 (21.0) 83 (25.2) 182 (20.6) 483 (21.1)
Any relapse 216 (22.1) 87 (26.4) 192 (21.7) 515 (22.5)
DMD: disease-modifying drug; ER: emergency room; sc IFNb-1a: subcutaneous interferon beta-1a.
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were statistically significantly greater than least
squares mean estimated all-cause healthcare costs
1 year after sc IFNb-1a initiation (US$65,408;
p< 0.0001; Table 4). All-cause healthcare costs
did not statistically significantly differ between
sc IFNb-1a (US$65,408) and teriflunomide
(US$64,203; p¼ 0.5849) or dimethyl fumarate (US
$67,784; p¼ 0.0809). All-cause healthcare costs
excluding DMD costs did not statistically signifi-
cantly differ between sc IFNb-1a (US$13,404) and
teriflunomide (US$15,205; p¼ 0.0704), fingolimod
(US$13,681; p¼ 0.6890), or dimethyl fumarate
(US$14,455; p¼ 0.0818). An interaction between
DMD and neurology visit 90 days pre-index was
significant in the all-cause cost model with and with-
out DMD costs. sc IFNb-1a patients had lower costs
than teriflunomide or dimethyl fumarate patients in
the group that did not have a neurology visit in the
90 days pre-index. There was also an interaction
between DMD and 90-day pre-index MRI in the
all-cost model with DMD costs removed. sc IFNb-
1a patients had lower costs than fingolimod patients
in the group that had a MRI claim in the 90 days
pre-index.
sc IFNb-1a initiation was also associated with lower
use of several outpatient management-related health-
care resources compared with the initiation of oral
DMDs, with the exception of inpatient stays and
LFTs for dimethyl fumarate (Table 5).
Discussion
Randomized controlled trials (RCTs) remain
the gold standard for assessing efficacy; however,
they are inadequate for addressing questions about
real-world comparative effectiveness of interven-
tions.15,16 Comparative effectiveness research
supports optimal decision making by stakeholders
in the healthcare system.17 No single study captures
all of the data required to make the best care deci-
sion for an individual patient.18 Inferences are based
on linking together findings from an array of studies
to determine the strength of evidence to support clin-
ical decision making.18
There were some pre-index differences among the
treatment groups, suggesting that patients initiating
oral DMD treatment differed from patients initiating
sc IFNb-1a treatment. These differences supported
Table 3. Logistic regression predictions of odds of relapse in the 1 year following treatment initiation.
Factors in multivariable analysis Estimate p value OR 95% CI
Teriflunomide (reference: sc IFNb-1a) 0.044 0.0477 1.357 1.000, 1.831
Fingolimod (reference: sc IFNb-1a) –0.009 0.7284 0.960 0.762, 1.209
Dimethyl fumarate (reference: sc IFNb-1a) 0.006 0.8316 1.021 0.846, 1.234
Sex, female (reference: male) –0.040 0.0595 0.847 0.712, 1.005
Age –0.063 0.0028 0.989 0.982, 0.996
Census region (reference: West)
East 0.044 0.2056 1.198 0.909, 1.592
Midwest 0.077 0.0310 1.353 1.032, 1.789
South 0.072 0.0450 1.324 1.010, 1.749
Unknown –0.011 0.6472 0.852 0.412, 1.639
Comorbidities (reference: not present)
Depression related 0.051 0.0107 1.226 1.048, 1.433
Thyroid 0.026 0.1991 1.139 0.932, 1.388
Inflammatory/autoimmune disease 0.034 0.0712 1.375 0.966, 1.933
CCI score 0.026 0.1790 1.044 0.979, 1.112
90-day pre-index neurology visit (reference: no visit) 0.069 0.0091 1.064 1.020, 1.116
90-day pre-index MRI (reference: no MRI claim) –0.030 0.1625 0.901 0.778, 1.042
90-day pre-index relapse (reference: no relapse) 0.178 <0.0001 2.146 1.823, 2.525
All-cause healthcare costs above the
median (reference: below median)
0.142 <0.0001 1.673 1.436, 1.950
Bold values denote statistically significant differences.
CCI: Charlson Comorbidity Index; CI: confidence interval; MRI: magnetic resonance imaging; OR: odds ratio; sc
IFNb-1a: subcutaneous interferon beta-1a.
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the use of a multivariable model. The logistic regres-
sion model of the primary outcome of relapse
showed that patients with MS newly initiating treat-
ment with teriflunomide had a small but statistically
significantly greater likelihood of relapse in the first
year compared with patients initiating sc IFNb-1a.
The comparisons of sc IFNb-1a with dimethyl fuma-
rate and fingolimod did not reach statistical signifi-
cance. Findings of this study are consistent with a
recently published retrospective chart review that
showed that patients treated with sc IFNb-1a had
similar relapse outcomes compared with dimethyl
fumarate-treated patients over 2 years.8
To our knowledge, this is the first published study to
use real-world data to compare costs between sc
IFNb-1a and oral DMDs. All-cause healthcare
costs were greater for fingolimod v. sc IFNb-1a.
When DMD costs were removed from the cost com-
parisons, absolute differences between products
were much smaller, as would be expected given
the magnitude of the drug v. medical costs. The
medical costs were numerically lowest for sc
IFNb-1a; however, statistically significant differen-
ces among the DMDs did not persist. Increased non-
DMD costs may be potential indicators of increased
disease activity. Evidence has shown that disease
severity has a correlation with quality of life in
patients with MS and with costs associated with
the disease.19,20 Also, for all-cause healthcare costs
excluding DMD costs, significant interactions
existed for having a neurology visit in the 90 days
pre-index or having a MRI claim in the 90 days pre-
index. These differences may reflect differences in
how the index drugs were prescribed, and the types
of follow-up care that were required.
There was greater resource use for some variables in
teriflunomide and fingolimod patients compared
with sc IFNb-1a patients, with the exception of inpa-
tient stays. The most notable results are that sc
IFNb-1a had lower estimated 1-year post-index
least square mean numbers of all-cause outpatient
visits, all-cause neurology visits, and all-cause ER
visits v. teriflunomide and fingolimod. Most differ-
ences for dimethyl fumarate were not statistically
significant. The number of inpatient stays in this
sample were relatively small and costs associated
with these stays represented a small proportion of
all-cause healthcare costs.
While more research is needed to assess the differ-
ences in these outcomes, possible explanations for
the findings include differences in types of physi-
cians managing these patients, unmeasured con-
founding differences, or differences in monitoring
requirements as specified in the prescribing informa-
tion for the individual DMDs.21
Limitations of this study include that the ICD-9-CM
code for systemic MS does not distinguish between
different MS types. Although the analysis aimed to
identify patients new to DMDs by requiring no
DMD for 12 months pre-index, it is possible that
patients received DMDs prior to this time and sub-
sequently discontinued treatment. Additionally,
challenges associated with patients changing health
plans or who are no longer in the database are pre-
sent. Covariates were used to adjust for baseline
differences and were checked for interactions with
the DMD variables; however, they were limited to
what was available in the database. Administrative
databases lack information regarding indication for
Table 4. Generalized linear models predicting patients’ healthcare costs (in US$) 1 year post-index
sc IFNb-1a
(n¼ 978)
Teriflunomide
(n¼ 330)
Fingolimod
(n¼ 883)
Dimethyl
fumarate
(n¼ 2284)
All-cause healthcare
costs, LS
mean (95% CI)
65,408
(63,253, 67,637)
64,203
(60,628, 67,989)
72,376
(69,881, 74,960)
67,784
(66,330, 69,269)
All-cause healthcare
costs excluding DMDs,
LS mean (95% CI)
13,404
(12,513, 14,358)
15,205
(13,523, 17,096)
$13,681
(12,729, 14,705)
14,455
(13,827, 15,113)
Healthcare expenditures adjusted to December 2015 US$ using the Medical Services component of the Consumer
Pricing Index.
Bold values denote statistically significant differences compared with the reference (sc IFNb-1a).
CI; confidence interval; DMD: disease-modifying drug; LS: least squares; sc IFNb-1a: subcutaneous interferon
beta-1a.
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use, clinical variables and physician characteristics
that could be important. As this dataset includes
administrative claims data for patients with commer-
cial health insurance, these findings may not be
generalizable to patients with other types of health-
care coverage. A 1-year follow-up period was used
in order to maximize capture of adequate numbers of
dimethyl fumarate patients after its approval by the
FDA; however, this is a short time horizon for
assessing effectiveness, tolerability and costs of
DMDs in MS. A longer follow-up duration would
be important to confirm these findings.
Conclusion
As RCTs evaluate very limited patient populations
under highly regulated clinical trial protocols, it is
also important to evaluate the comparative effective-
ness of clinical interventions. In this real-world eval-
uation, patients initiating sc IFNb-1a had better
relapse outcomes compared with patients initiating
teriflunomide, and lower all-cause healthcare costs
compared with patients initiating fingolimod over a
1-year follow-up. As more data on oral DMDs
become available, a longer follow-up would be of
interest for assessing comparative effectiveness over
a longer time horizon.
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